Skip to main content
. 2014 Feb 18;7(1):86–91. doi: 10.3980/j.issn.2222-3959.2014.01.15

Figure 1. Visual acuity and macular thickness improves after treatment with bevacizumab or ranibizumab.

Figure 1

A: The mean logMAR visual acuity decreases (improves) after treatment with bevacizumab or ranibizumab. There are no significant differences between the two groups; B: The mean central subfield thickness measured on SD-OCT also decreases with treatment with no significant differences between the two groups. Mean±SEM.